iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Down 42.2% in May

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totaling 27,456 shares, a decline of 42.2% from the April 30th total of 47,511 shares. Based on an average daily volume of 57,909 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.5% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Portland Global Advisors LLC lifted its position in iShares Genomics Immunology and Healthcare ETF by 0.7% in the third quarter. Portland Global Advisors LLC now owns 103,007 shares of the company’s stock worth $2,432,000 after purchasing an additional 684 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of iShares Genomics Immunology and Healthcare ETF by 8.4% in the third quarter. Ameriprise Financial Inc. now owns 71,473 shares of the company’s stock valued at $1,688,000 after buying an additional 5,540 shares during the period. Finally, Triumph Capital Management bought a new position in iShares Genomics Immunology and Healthcare ETF during the third quarter valued at about $35,000.

iShares Genomics Immunology and Healthcare ETF Trading Up 3.9%

IDNA traded up $1.14 on Thursday, reaching $30.03. The company had a trading volume of 39,347 shares, compared to its average volume of 40,581. The company has a market capitalization of $163.66 million, a P/E ratio of 14.76 and a beta of 0.97. The company has a fifty day moving average of $29.54 and a 200-day moving average of $28.62. iShares Genomics Immunology and Healthcare ETF has a one year low of $20.15 and a one year high of $31.41.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.